Benefits of CFT vs. In Vivo FLI/BLI
Cryo-Fluorescence Tomography (CFT) is a transformative 3D approach to imaging drug distribution and protein expression (PK/PD) in whole animals. Compared to in vivo optical imaging techniques such as 2D fluorescence imaging (FLI) and bioluminescence imaging (BLI), CFT provides high resolution, high sensitivity anatomical and fluorescence images designed to help you discover more in biological and drug research. EMIT Imaging offers contract services and instrumentation (XerraTM), allowing for a seamless integration into your existing imaging workflows. See what you’re missing and utilize CFT to better visualize:
- Whole-body drug distribution and delivery
- Screening candidate drugs and delivery systems
- Whole-body therapeutic protein expression
- Multiplexed co-localization of drug with targets
- On and off target tissue identification
Fibroblast-activation protein: Whole Body Biodistribution Copyright 2023 Ratio Therapeutics Inc., used with permission
CFT vs. In Vivo FLI
Multiplexing: Visualize 3D Co-localization of Drug and Tumor Cells
Findings: CFT shows high-resolution, 3D co-localization of tumor cells and drugs, complementing and expanding 2D in vivo imaging
Details
- Orthotopic ovarian cancer model with tdTomato-expressing cells
- Injected HER2-targeted antibody labeled with AF647
Ovarian Cancer cells (tdTomato)
Her2-Targeting Protein (AF647)
Intrathecal Injection: Whole Body Distribution of Labeled ASO
Findings: CFT is superior to surface fluorescence due to its depth limitations (signal loss) and poor resolution
Details:
- Cy5-labeled ASO at day 15 following IT injection
- Full visualization of spinal column into the cisterna magna
- CFT detects bioD and clearance: GI, lympathic, nasal turbinate, etc.
- CFT is 3D and high resolution: <50mm versus >1mm in optical and nuclear medicine imaging
–> Signal loss due to depth, note the spine in CFT
-> Site of Injection
CFT vs. In Vivo BLI
Understanding of Disease Models
Findings: CFT image shows the primary tumor extent and heterogeneity as well as the metastatic lesions in the lungs
Details:
- MDA-MB-231 human breast adenocarcinoma cells were engineered to express both firefly luciferase and DsRed
- The in vivo bioluminescence image shows the flank tumor and can be used to track progression
DsRed mice provided by John Ronald, Robarts Research Institute
BLI (ffluc)
CFT (DsRed)
